@davistalkspeps
4 posts audited · 16 claims analysed
Science evidence grade
Based on 16 claims across 4 audits
8
Supported
50%
2
Overstated
13%
0
Misleading
0%
6
No Evidence
38%
Share this evidence grade
Claim-level evidence grades — not a character judgment. Methodology · Right of reply · Leaderboards
What @davistalkspeps claims actually are
We separate claims into three buckets: backed by evidence, factually incorrect, and grey — like animal-only findings sold as human fact (e.g. BPC-157 “fixes Achilles” from rat studies).
Evidence-based
50%
8 claims
Claims that align with published human or clinical evidence at the stated strength.
Ex: “Semaglutide can reduce body weight in adults with obesity” — supported by large RCTs.
Factually incorrect
0%
0 claims
Claims that conflict with the evidence, invent certainty, or omit critical safety/context in a misleading way.
Ex: “Peptides have no side effects” — contradicts known adverse-event profiles.
Grey / overstated
50%
8 claims
Plausible direction but wrong certainty — animal-only data sold as human fact, dose/effect overstated, or no adequate published support yet.
Ex: “BPC-157 fixes Achilles tears” — often rests on rodent tendon models, not proven human Achilles repair trials.
Evidence mix
Share of audited claims in each bucket
Verdict detail
Grey splits into overstated (wrong certainty) vs no published support
Claims over time
Stacked by bucket as audits land — plus the running evidence grade
Gold line = running science evidence grade (Supported + ½ Overstated ÷ total claims).
Audit history(4 posts)
“how long it stays good”
Claims 1 and 2 (powder stability timelines and freezer extension) lack any peer-reviewed or clinical trial evidence specific to retatrutide and should be considered unvalidated assertions. Claims 3, 4, and 5 reflect sound microbiological and pharmaceutical handling principles that are well-established in general sterility and compounding standards, though they are not supported by retatrutide-specific studies. The creator appears to be applying general peptide storage wisdom rather than citing validated retatrutide data; this is reasonable practice guidance but should not be represented as retatrutide-specific science without evidence.
“it stopped working”
All three claims about Reta—its seven-day half-life, the five-week clearance timeline, and the two-to-three week resensitization window—lack supporting peer-reviewed literature, registered clinical trials, or cited studies. While Claims 2 and 3 follow logically from Claim 1, none of the claims have been validated by published pharmacokinetic or pharmacodynamic data. Without foundational evidence for Reta's basic PK profile or tolerance dynamics, these claims cannot be assessed as scientifically supported.
“what to know”
GHK-Cu's collagen stimulation and skin repair claims are supported by active Phase II and completed Phase IV human clinical trials specifically testing these endpoints—a credible evidence tier. Anti-inflammatory properties and 'overall recovery' lack direct scientific support in the current literature. The strongest claims (collagen, skin repair) have human trials actively enrolled or completed, making them the most scientifically grounded among bioregulatory peptides in this category.
“can it stop working?”
Claims 1 and 2 are well-supported by peer-reviewed evidence: GLP-1 receptor agonists do demonstrably reduce appetite, food cravings, and 'food noise' while improving satiety—this is documented in the 2025 Yale clinical review and aligns with multiple human trials. However, claims 3 and 4—that appetite suppression fades after several weeks of continued use and that the body 'adapts' to the compound—lack direct clinical evidence in published literature or registered trials. The creator describes a real phenomenon reported anecdotally in the GLP-1 user community and acknowledged in PeptIQ's internal knowledge base, but no indexed peer-reviewed studies or human RCTs validate this specific timeline or mechanism of tolerance. The post's early claims are solid; the later claims about habituation and adaptation are plausible but currently unsupported by published science.
Audit another post from @davistalkspeps
Paste their social post link to add a new audit